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Abstract
Tyrosine metabolism of toxohormone-treated mice and acatalasemic patient was not dis-
turbed. These facts do not concur with the report of Zannoni and Bert who stated that catalase
was an essential factor for the oxidation of p-hydroxyphenylpyruvic acid.
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Recently, Zannoni and BERT1 have reported that catalase was an
essential component for the oxidation of p-hydroxyphenylpyruvic acid to
homogentisic acid in the liver. If this is the case, animals which contain
reduced amount of catalase in the liver should have a disturbed tyrosine
metabolism. Among such animals, a human acatalasemic patient and
the toxohormone treated mice were used for testing their tyrosine metabo-
lism.
Acatalasemic patient was at first found to have no catalase in his blood
by TAKAHARA2 of Okayama University, and has also proved to contain
no catalase in his liver by YOSHIYA 3. Toxohormone prepared from can-
cer tissues is well known to be capable of reducing liver catalase of mice
when it is injected 4.
In the present experiment, tyrosine was loaded to such animals and
the urinary p-hydroxyphenylpyruvic acid was determined, and no diffe-
rences were detected between normal and reduced catalase groups.
MATERIAL AND METHODS
Toxohormone was prepared from human gastric cancer* by the me-
thod of Ono et a1. 8. D, L-Tyrosine used was commercial product. Catalase
was assayed by a modified method of BONNICHSEN, CHANCE, and
THEORELL 6. p-Hydroxyphenylpyruvic acid was estimated by two diffe-
rent methods. One is Millon's reaction 7 which is specific to the phenol
group, and the other is Penrose and Quastels' reaction8 which is cha-
racteristic of the ketone group.
RESULTS
i. Liver catalase activity of normal and toxohormone treated mice:
* These materials were kindly supplied by Dr. M. SHIMIZU of St. Maria Hospital
in Himeji.
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Mice were fed by the synthetic diet 9• Toxohormone was dissolved in the
minimum amount of dilute hydrochloric acid and the solution was injected
intraperitoneally into mice after adjusting to pH 6 by alkali. Twenty·four
hours after toxohormone injection, mice were killed by exsanguination
and the liver catalase activity was determined. As shown in Fig. 1, the
Fig.1. Liver Catalase Activity of Normal
and Toxohormone Treated Mice.
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Dotted Line: Toxohormone Treated Mice
toxohormone used was quite effective for liver catalase depression.
ii. Urinary p-hydroxyphenylpyruvic acid of normal and toxohor-
mane treated mice: Table 1 shows the amount of p-hydroxyphenylpyruvic
Table 1. p.Hydroxyphenyl pyruvic acid excreted in the urine of normal
mice (expressed in mg. per day)
I
------ ._~--- .--
IExp. No. Penrose & Quastels' R. Millon's R.
1 I 1.30 I 0.56
2 I 0.84 I 0.27
3 I 1.20 I 0.28
4 I 1.30 I 0.50
acid excreted per day in the urine of normal mice. The urine of toxohormone
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treated mice was collected for 24 hours after injection of toxohormone.
Table 2 shows the amount of urinary p-hydroxyphenylpyruvic acid excreted
by toxohormone treated mice per day. No appreciable difference was obs-
erved between two groups.
Table 2. p-Hydroxyphenylpyruvic acid excreted in the urine of
toxohormone treated mice (expressed in mg. per day)
Exp. No. I Penrose & Quastels' R. I Millon's R.
7
I
1. 20 I 0.42
8
I
1.00 I 0.29
10 I 1.10 I 0.36I
12
I
0.62 I 0.45
13 I 1.50 I 0.52
111. Effects of ty rosine administration on the urinary excretion of
p-hydroxyphenylpyruvic acid of normal and toxohormone treated mice:
Mice fed by the synthetic diet which was loaded by 1 mg. of tyrosine per
day and the same experiments were performed as described in H. Results
are shown in Table 3. No difference between normal and toxohormone
treated mice were demonstrated either.
Table 3. p.Hydroxyphenylpyruvic acid excreted in the urine of mice
loaded by tyrosine (expressed in mg. per day)
I No. I Penrose & Quastels' R. I Millon's R.I Exp.
15 0.15 i 0.13I
Normal I
16 0.58 I 0.29
Toxohormone i 18 0.14 0.14j
treated -
mice I 20 0.44 0.31I
iV. Effects of tyrosine on the urinary excretion of p-hydroxyphenyl-
pyruvic acid of normal and acatalasemic patient: Twenty-four hour's
urine of two normal women and a female acatalasemic patient before and
after tyrosine administration was collected in the morning for three days.
In the morning of the second day, 2 g. of tyrosine was administered
orally. As shown in Table 4, the urinary excretion of p-hydroxyphenyl-
pyruvic acid was not affected by tyrosine administration in both cases.
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Table 4. p·Hydroxyphenylpyruvic acid excreted in the urine of normal
and acatalasemic women (expressed in mg. per day)
I Date I Penrose & Quastels' R. I Millon's R.I
1st 181 196
Patient 2nd 170 225
3rd 174 178
1st 233 223
Normal 2nd 265 310
3rd 182 280
1st 162 -
Normal 2nd 178 -
3rd 110 -
DISCUSSION
Results obtained in the present experiments did not agree with the
report of Zannoni and BERT 1 cited in the preface of this paper. By using
tumor bearing mice Dr. SUDA10 has also shown that catalase is not an
essential factor for the oxidation of p-hydroxyphenylpyruvic acid. Further-
more, while the present paper work was in preparation for press, HARGER
et al. 11 have reported that catalase was required only under certain
assay conditions to avoid inactivation of p-hydroxyphenylpyruvic acid
oxidase during its reaction. These facts indicate that catalase does not
participate in the oxidation of p-hydroxyphenylpyruvic acid.
SUMMARY
Tyrosine metabolism of toxohormone·treated mice and acatalasemic
patient was not disturbed.
These facts do not concur with the report of Zannoni and Bert who
stated that catalase was an essential factor for the oxidation of p-hydroxy-
phenylpyruvic acid.
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